It has been a long road but Sweden's InDex Pharmaceuticals Holding AB is moving its investigational ulcerative colitis drug cobitolimod into Phase III armed with a sizeable cash pot following a successful financing.
The Stockholm-based group has signed off a rights issue that has raised SEK533m ($64.2m) consisting of around 444 million new...